Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Retrieved on: 
수요일, 11월 8, 2023
INAF, Meal, Research, Trial of the century, Faculty, Fasting, Stomach, Peptide YY, Endocrine gland, Membrane protein, GIP, Human, Regulatory News Service, Université Laval, Hyperinsulinemia, Agonal respiration, PYY, Type 2 diabetes, Inflammation, Fibrinogen, Metabolism, Volunteering, Development, Glycated hemoglobin, Phase, Prediabetes, Food court, Lipid, Disease, Risk, Plant, Medicine, Research and development, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical school, Industrial Affairs Committee (Iceland), Partnership, Sensation, Blood, Nutrition, Hormone, CET, Safety, Insulin resistance, Overweight, Gastric inhibitory polypeptide, Glucose, Insulin, Pharmaceutical industry, Dietary supplement, Medical device, Animal feed

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Key Points: 
  • Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The study confirms TOTUM•63's efficacy results, in particular the lasting reduction in glycated hemoglobin, one of the main markers of prediabetes and type 2 diabetes.
  • It demonstrates TOTUM•63's multi-target mode of action in subjects at risk, improving the efficacy of energy metabolism, particularly after meals.
  • Mode of action clinical results: TOTUM•63 regulates energy metabolism
    In addition to the positive clinical efficacy studies already conducted, the mode of action study was carried out on 19 overweight or obese volunteers at risk of developing type 2 diabetes.

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors

Retrieved on: 
화요일, 4월 5, 2022
Private Securities Litigation Reform Act, Medicine, Cancer, Company, Faculty, Glioblastoma, Forward-looking statement, Multimedia, Neuroscience, University, Vaccine, Survival, Research, Standard of care, CEO, Severe acute respiratory syndrome coronavirus 2, Neoplasm, Communication, Industry, Medical school, Eli Lilly, COVID-19, Eli Lilly and Company, Melanoma, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Amgen, Pharmaceutical industry

IRVINE, Calif., April 5, 2022 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors.

Key Points: 
  • IRVINE, Calif., April 5, 2022 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors.
  • Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world's largest biotechnology company.
  • Before joining Amgen, Dr. Fibiger served as vice president of Neuroscience Discovery Research and Clinical Investigation at Eli Lilly and Company.
  • "Dr. Fibiger is a particularly meaningful addition to our board as we transition to Phase 3 clinical trials," said Dr. Hans S. Keirstead, AIVITA Biomedical's chairman and CEO.

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Retrieved on: 
화요일, 2월 1, 2022
Principal investigator, Safety, Risk, Patient, Lists of diseases, Therapy, Private Securities Litigation Reform Act, FA, FXN, Infection, Amgen, Clinical trial, FACC, SEC, EMA, Biotechnology, Friedreich's ataxia, Neuroscience, Nature, Research, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Disease, Massachusetts General Hospital, Program, Hospital, U.S. Securities and Exchange Commission, Drug discovery, Neurology, Metabolism, Weill Cornell Medicine, Cardiovascular disease, GLOBE, Degenerative disease, NIH, Time, Cornell University, Cardiology, Industry, FDA, Security (finance), Harvard Medical School, RNA, Genetics, Nasdaq, Faculty, Drug, Pharmaceutical industry, Brigham, Alnylam Pharmaceuticals, Design, Medicine

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer.

Key Points: 
  • CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer.
  • I am thrilled to welcome Jae to Design, particularly as we prepare to embark on the important transition to a clinical stage company and initiation of our Phase 1 clinical trial in patients with Friedreich ataxia, said Joo Siffert, M.D., president and chief executive officer of Design Therapeutics.
  • Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC gene targeted chimera small molecules.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

H3 Biomedicine Welcomes Dr. Richard Woodman to its Board of Directors

Retrieved on: 
월요일, 1월 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lymphatic system, Eisai, Woodman, Breast cancer, Johnson & Johnson, Growth, Hepatocellular carcinoma, Hematology, 2009 Davis Cup, Industry, Head, Cancer, Patient, Board, Medical school, Precision medicine, Oncology, Medical research, Doctor of Philosophy, LP, Novartis, Genomics, University, Faculty, Research institute, Medical Affairs Bureau, Board of directors, Division, Department, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical imaging, Medicine, Research, H3

H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D.

Key Points: 
  • H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D.
  • to its Board of Directors (Board).
  • With over 18 years of oncology-focused pharmaceutical experience at both large and small biotechnology organizations and his years in academia, Dr. Woodman brings extensive industry and clinical knowledge to H3.
  • Dr. Woodman has already made significant contributions since joining Eisai almost one year ago and we are delighted to welcome him to our Board.